Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 6, 2018, Pages

  Gorelik, Einat ^a,b   Masarwa, Reem ^a   Perlman, Amichai ^a   Rotshild, Victoria ^a   Muszkat, Mordechai ^c   Matok, Ilan ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Arrhythmia; Azithromycin; Cardiac arrest; Cardiac death; Cardiovascular; Clarithromycin; Erythromycin; Macrolide; Mortality; Myocardial infarction; Roxithromycin; Stroke; Torsades de pointes; Ventricular tachyarrhythmia

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG SAFETY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; META ANALYSIS; NETWORK META-ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDES; MYOCARDIAL INFARCTION; NETWORK META-ANALYSIS; RISK FACTORS;

EID: 85047602531     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00438-18     Document Type: Article

References (54)

1. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. 2004. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351:1089–1096. https://doi.org/10.1056/NEJMoa040582.
2. Abo-Salem E, Fowler JC, Attari M, Cox CD, Perez-Verdia A, Panikkath R, Nugent K. 2014. Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther 32:19–25. https://doi.org/10.1111/1755-5922.12054.
3. Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, Mei WY, Liu LJ, Long M, Yao FJ, Liu J, Liao XX, Du ZM, Dong YG, Ma H, Xiao HP, Wu SH. 2015. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66:2173–2184. https://doi.org/10.1016/j.jacc.2015.09.029.
4. Owens RC, Nolin TD. 2006. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 43:1603–1611. https://doi.org/10.1086/508873.
5. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. 2012. Azithromycin and the risk of cardiovascular death. N Engl J Med 366:1881–1890. https://doi.org/10.1056/NEJMoa1003833.
6. US Food and Drug Administration (FDA). 2013. FDA drug safety communication: azithromycin (zithromax or zmax) and the risk of potentially fatal heart rhythms. US Food and Drug Administration, Silver Spring, MD.
7. US Food and Drug Administration (FDA). 2018. FDA drug safety communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease. US Food and Drug Administration, Silver Spring, MD.
8. Li X, Wang M, Liu G, Ma J, Li C. 2016. Association of macrolides with overall mortality and cardiac death among patients with various infections: a meta-analysis. Eur J Intern Med 28:32–37. https://doi.org/10.1016/j.ejim.2015.09.009.
9. Wong AYS, Chan EW, Anand S, Worsley AJ, Wong ICK. 2017. Managing cardiovascular risk of macrolides: systematic review and meta-analysis. Drug Saf 40:663–677. https://doi.org/10.1007/s40264-017-0533-2.
10. Root AA, Wong AYS, Ghebremichael-Weldeselassie Y, Smeeth L, Bhaskaran K, Evans SJW, Brauer R, Wong ICK, Navaratnam V, Douglas I. 2016. Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. Br J Clin Pharmacol 82:512–521. https://doi.org/10.1111/bcp.12983.
11. Wong AYS, Root A, Douglas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, Siu C-W, Smeeth L, Wong ICK. 2016. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 352:h6926. https://doi.org/10.1136/bmj.h6926.
12. Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, Garg AX. 2016. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 188:E120–E129. https://doi.org/10.1503/cmaj.150901.
13. Quinn KL, Macdonald EM, Gomes T, Mamdani MM, Huang A, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network (CDSERN). 2017. Macrolides, digoxin toxicity and the risk of sudden death: a population-based study. Drug Saf 40:835– 840. https://doi.org/10.1007/s40264-017-0539-9.
14. Berni E, De Voogd H, Halcox JP, Butler CC, Bannister CA, Jenkins-jones S, Jones B, Ouwens M, Currie CJ. 2017. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open 7(1):e013398. https://doi.org/10.1136/ bmjopen-2016-013398.
15. Reference deleted.
16. Schink T, Poluzzi E, Frøslev T, Molokhia M, Diemberger I 2017. Use of azithromycin and risk of ventricular arrhythmia. CMAJ 189:E560–E568. https://doi.org/10.1503/cmaj.160355.
17. Zambon A, Polo Friz H, Contiero P, Corrao G. 2009. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 32:159–167. https://doi.org/10.2165/00002018-200932020-00008.
18. Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. 2015. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and -lactam/-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 60:566–577. https://doi.org/10.1093/cid/ciu914.
19. Goldstein LH, Gabin A, Fawaz A, Freedberg NA, Schwartz N, Elias M, Saliba W. 2015. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia 1042–1048. Pharmacoepidemiol Drug Saf 24:1042–1048. https://doi.org/10.1002/pds.3842.
20. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM. 2014. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 12:121–127. https://doi.org/10.1370/afm.1601.
21. Jespersen CM, Kolmos HJ, Frydendall N, Hilden J, Gluud C, Hansen JF. 2009. Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial. J Antimicrob Chemother 64:411–415. https://doi.org/10.1093/jac/dkp190.
22. Reference deleted.
23. Reference deleted.
24. Svanström H, Pasternak B, Hviid A. 2013. Use of azithromycin and death from cardiovascular causes. N Engl J Med 368:1704–1712. https://doi.org/10.1056/NEJMoa1300799.
25. Svanström H, Pasternak B, Hviid A. 2014. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 349:g4930. https://doi.org/10.1136/bmj.g4930.
26. Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, Van Der Lei J, De Graeff PA, Kingma JH, Stricker BHC. 2005. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26:2007–2012. https://doi.org/10.1093/eurheartj/ehi312.
27. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS. 2002. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation 105:1555–1560. https://doi.org/10.1161/01.CIR.0000012544.07696.1F.
28. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, Johnson CS, Alvarez CA, Frei CR, Good C, Restrepo MI, Downs JR, Anzueto A. 2014. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 311:2199–2208. https://doi.org/10.1001/jama.2014.4304.
29. Luchsinger A, Pablos-me A, Knirsch C, Rabinowitz D, Shea S. 2002. Relation of antibiotic use to risk of myocardial infarction in the general population 89:18–21.
30. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, Singanayagam A, Hill AT, Chalmers JD. 2013. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 346:f1235. https://doi.org/10.1136/bmj.f1235.
31. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. 1999. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427– 431. https://doi.org/10.1001/jama.281.5.427.
32. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C, ACES Investigators. 2005. Azithromycin for the secondary prevention of coronary events. N Engl J Med 352:1637–1645. https://doi.org/10.1056/NEJMoa043526.
33. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. 1999. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 20:121–127. https://doi.org/10.1053/euhj.1998.1283.
34. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. 2000. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102: 1755–1760. https://doi.org/10.1161/01.CIR.102.15.1755.
35. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S. 2001. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84(Suppl 3): S669–S675.
36. Vainas T, Stassen FRM, Schurink GWH, Tordoir JHM. 2005. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (space trial): a randomised clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 29:403–411. https://doi.org/10.1016/j.ejvs.2005.01.001.
37. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. 1997. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404–407. https://doi.org/10.1161/01.CIR.96.2.404.
38. Stone AFM, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC. 2002. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA). Circulation 106:1219–1223. https://doi.org/10.1161/01.CIR.0000027820.66786.CF.
39. O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. 2003. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290:1459–1466. https://doi.org/10.1001/jama.290.11.1459.
40. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, Maurer G, Mahrer P, AZACS Investigators. 2003. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361:809 – 813. https:// doi.org/10.1016/S0140-6736(03)12706-7.
41. Berg HF, Maraha B, Scheffer G-J, Quarles-van Ufford M, Vandenbroucke-Grauls CMJE, Peeters MF, Kluytmans JAJW. 2005. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 40:358 –365. https://doi.org/10.1086/427111.
42. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Jogethaei N, da Costa CP, Wagner H, Schomig A. 2001. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neo-intima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357:2085–2089. https://doi.org/10.1016/S0140-6736(00)05181-3.
43. Mosholder AD, Lee J-Y, Zhou EH, Kang EM, Ghosh M, Izem R, Major JM, Graham DJ. 2017. Long-term risk of acute myocardial infarction, stroke and death with outpatient use of clarithromycin: a retrospective cohort study. Am J Epidemiol.
44. Kannankeril P, Roden DM, Darbar D. 2010. Drug-induced long QT syndrome. Pharmacol Rev 62:760 –781. https://doi.org/10.1124/pr.110.003723.
45. Kutlin A, Roblin PM, Hammerschlag MR. 2002. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 46:409 – 412. https://doi.org/10.1128/AAC.46.2.409-412.2002.
46. Bosnar M, Bos B, Marjanovic N, Glojnaric I, Ognjen C, Parnham MJ, Erakovic V. 2009. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1. J Pharmacol Exp Ther 331:104–113. https://doi.org/10.1124/jpet.109.155838.
47. Stein G, Havlichek D. 1992. The new macrolide antibiotics. Azithromycin and clarithromycin. Postgr Med 92:269–272, 277–282. https://doi.org/10.1080/00325481.1992.11701404.
48. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. 2013. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310:2544–2553. https://doi.org/10.1001/jama.2013.282426.
49. Labro MT. 1998. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 41(Suppl B):37–46. https://doi.org/10.1093/jac/41.suppl_2.37.
50. Moher D. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264. https://doi.org/10.7326/0003-4819-151-4-200908180-00135.
51. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. 2000. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed on 4 April 2018.
52. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, Cochrane Bias Methods Group Cochrane Statistical Methods Group. 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928.
53. Rücker G, Schwarzer G. 2015. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Meth-odol 15:1–9. https://doi.org/10.1186/1471-2288-15-1.
54. Schwarzer G. 2017. Package “netmeta.” 0.9-2. https://cran.r-project.org/web/packages/netmeta/netmeta.pdf.